Telesis Bio, a leading provider of DNA and mRNA synthesis solutions to accelerate therapeutic discovery with fast and flexible on-site automated foundries, today announced that it has entered into a ...

GlobalVetLink (GVL), the leader in digital animal health compliance solutions, has announced a new integration with Provet Cloud, a leading cloud-based veterinary practice management system. This ...

The Rising Need for Efficient and Effective Drug Discoveries Worldwide is Expected to Create Lucrative Growth Opportunities in the Market.

The study provides convincing evidence for variable regeneration efficiency among planarian species that will be of interest to developmental biologists interested in regeneration. However, some of ...

A child with a rare genetic disorder — spinal muscular atrophy type I — was treated prenatally for the first time. Courtesy of Jakob Owens  via Unsplash During an amniocentesis test, a long, thin ...

With the long-term goal of creating living cells from non-living components, scientists in the field of synthetic biology work with RNA origami. This tool uses the multifunctionality of the natural ...

A novel strategy using lipid nanoparticles to reprogram liver immunity shows promise in generating antitumor responses ...

Following the COVID-19 pandemic, mRNA-based vaccines have been shown to provide rapid and precise immune responses, however, this technology has much wider applications. Many leading pharma and ...

A few years ago, Moderna (NASDAQ: MRNA) stock soared on the back of the highly successful vaccine it developed in record time. At its peak in 2021, Moderna traded for over $450 per share.

CureVac and partner GSK are, meanwhile, also developing an mRNA-based flu vaccine, but are a little further back in development, as their shot is in phase 1 testing.